These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11975700)

  • 1. Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses.
    Chow AT; Chen A; Lattime H; Morgan N; Wong F; Fowler C; Williams RR
    J Clin Pharm Ther; 2002 Apr; 27(2):143-50. PubMed ID: 11975700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
    Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
    Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
    Chien SC; Rogge MC; Gisclon LG; Curtin C; Wong F; Natarajan J; Williams RR; Fowler CL; Cheung WK; Chow AT
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2256-60. PubMed ID: 9333057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
    Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.
    Rebuck JA; Fish DN; Abraham E
    Pharmacotherapy; 2002 Oct; 22(10):1216-25. PubMed ID: 12389872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical pharmacokinetics of levofloxacin.
    Fish DN; Chow AT
    Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients.
    Piscitelli SC; Spooner K; Baird B; Chow AT; Fowler CL; Williams RR; Natarajan J; Masur H; Walker RE
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2323-7. PubMed ID: 10471591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.
    Gotfried MH; Danziger LH; Rodvold KA
    Chest; 2001 Apr; 119(4):1114-22. PubMed ID: 11296178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial.
    Graham DR; Talan DA; Nichols RL; Lucasti C; Corrado M; Morgan N; Fowler CL
    Clin Infect Dis; 2002 Aug; 35(4):381-9. PubMed ID: 12145720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.
    Chow AT; Fowler C; Williams RR; Morgan N; Kaminski S; Natarajan J
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2122-5. PubMed ID: 11408234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid.
    Child J; Mortiboy D; Andrews JM; Chow AT; Wise R
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2749-51. PubMed ID: 8593013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue pharmacokinetics of levofloxacin in human soft tissue infections.
    Bellmann R; Kuchling G; Dehghanyar P; Zeitlinger M; Minar E; Mayer BX; Müller M; Joukhadar C
    Br J Clin Pharmacol; 2004 May; 57(5):563-8. PubMed ID: 15089808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora.
    Edlund C; Sjöstedt S; Nord CE
    Scand J Infect Dis; 1997; 29(4):383-6. PubMed ID: 9360254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose.
    Wagenlehner FM; Kinzig-Schippers M; Sörgel F; Weidner W; Naber KG
    Int J Antimicrob Agents; 2006 Dec; 28(6):551-9. PubMed ID: 17101261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections.
    Nicodemo AC; Robledo JA; Jasovich A; Neto W
    Int J Clin Pract; 1998 Mar; 52(2):69-74. PubMed ID: 9624783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative assessment of ocular tissue distribution of drug-related radioactivity after chronic oral administration of 14C-levofloxacin and 14C-chloroquine in pigmented rats.
    Tanaka M; Takashina H; Tsutsumi S
    J Pharm Pharmacol; 2004 Aug; 56(8):977-83. PubMed ID: 15285841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose.
    Wagenlehner FM; Kinzig-Schippers M; Tischmeyer U; Wagenlehner C; Sörgel F; Dalhoff A; Naber KG
    Int J Antimicrob Agents; 2006 Jan; 27(1):7-14. PubMed ID: 16343856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.